Partner

Partner

恒瑞 豪森 复兴医药 君实
康芳生物 石药集团 Henlius 先声药业
中国生物 科兴 beigene iqvia
齐鲁制药 沃森生物 zfsw astrazeneca
merck roche pfizer 正大天晴
康龙化成 stem斯丹姆 key tech  康特瑞科 昆拓
和铂 harbour 科伦 康宁杰瑞 丽珠医药
艾美疫苗 cdbio 昆翎 bestudy
缔脉 海金格医药 佳生 ppc 应世生物
华辉安健 reistone abbisko 创胜集团
信诺维 药明巨诺 华奥泰生物 康诺亚
天广实 adagene elpiscience 扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团
扬子江药业集团

Video Center

Pain points collection and experience sharing of global clinical trials (including the supply chain solutions)

From the point of view of clinical operation, the drug scale-up estimation + global project management + global regulatory compliance was discussed; and drug transport consideration in epidemic situation - remote blinding, D2P, cross-site drug taking and other special case considerations can be brought in

Pain point collection and solutions for data management of international multi-center clinical trials

The journey to the sea of Chinese pharmaceutical companies is walking forward, being full of thistles and thorns. In this topic, we discussed the key points of data management in the whole lifecycle of MRCT, the problems and challenges of data management in MRCT projects, and effective solutions with industry colleagues.

Epidemic normalization, clinical project operation in special times

In the global situation and impact of COVID-19 pandemic, it becomes so important in this period for the following aspects, how to conduct the tests under study, especially the global clinical projects successfully, what dimension of risks are to be considered, and how to develop measures in line with project management.

Discussion on trend of global device global trial

From the current situation of medical device clinical trial industry in China, we discussed the series of impacts of the new regulations on registrants, clinical agencies, contract research organizations (CROs) and the future industry globalization, taking into account the new changes faced by medical device clinical trials under the new regulation environment

Attempts from multi-center electronic medical records to manually built Pseudo-Registry

Attempts for governing retrospective data

Qualifications and IP

Contact Us

bd@ishanhu.com 400-1616-835
Contact us
bd@ishanhu.com

400-1616-835